Epi Soul logo image Epi Soul logo image
  1. UW Home |
  2. SPH  |
  3. Other Departments |
Loading
online giving









































Catherine Stehman-Breen, MD, MS, BS


Affiliate Associate Professor, Epidemiology

Vice President, Clinical Development,

My academic career focuses on clinical research in bone, kidney and neurologic diseases. The goal of these clinical trial programs is to bring innovative therapeutics to people with serious illnesses. My areas of focus are osteoporosis, hyperparathyroidism in kidney disease and migraine.

Catherine received her medical degree from University of Chicago in 1990. She completed her residency and fellowship training at the University of Washington where she also received a Masters of Science degree in Epidemiology. She spent six years as a Faculty member in the Division of Nephrology at University of Washington. Her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in renal disease patients. Catherine joined Amgen in 2003 where she became the Global Development Leader for Aranesp and Epogen. In 2006, she became the Therapeutic Area Head for Bone where she was responsible for the Prolia and romosozumab programs. She is currently the Therapeutic Area Head for Bone, Nephrology and Neuroscience and is responsible for clinical programs related to bone loss, nephrology and several neuroscience indications.


Contact Information
Amgen Inc.
Box MS38-2-C
One Amgen Center Drive
Thousand Oaks, CA 91320
Tel: 805-447-7791
Fax: 805-499-0947
http://www.amgen.com/
cstehman@amgen.com


Affiliations
National Institute of Health

Research Interests
Metabolic bone disease and cardiovascular disease in ESRD, osteoporosis

Education
MS, Epidemiology, University of Washington 1996
MD, Medicine, University of Chicago 1990
BS, Biology, Colby College 1985

Projects

  • Romosozumab, a bone forming agent for the treatment of osteoporosis in patients at high risk for fracture
  • Denosumab, an antiresorptive agent for the treatment of osteoporosis in patients at high risk for fracture
  • AMG 334, a CGRP receptor antagonist for the prophylaxis of migraine
  • AMG 416, a calcimimetic for the treatment of hyperparathyroidism
  • Cinicalcet, a calcimimetic for the treatment of hyperparathyroidism


Selected Publications
Seliger SL, Siscovick DS, STEHMAN-BREEN CO, Gillen DL, Fitzpatrick A, Bleyer A, Kuller LH. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study.J Am Soc Nephrol. 2004 Jul;15(7):1904-11.

Mittalhenkle A, Gillen DL, STEHMAN-BREEN CO. Increased risk of mortality associated with hip fracture in the dialysis population.Am J Kidney Dis. 2004 Oct;44(4):672-9.

Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, STEHMAN-BREEN C. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004 Nov;66(5):2010-6.

Fried L, Solomon C, Shlipak M, Seliger STEHMAN-BREEN C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman  A. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals.J Am Soc Nephrol. 2004 Dec;15(12):3184-91.

Seliger SL, Longstreth WT Jr, Katz R, Manolio T, Fried LF, Shlipak M, STEHMAN-BREEN CO, Newman A, Sarnak M, Gillen DL, Bleyer A, Siscovick DS. Cystatin C and Subclinical Brain Infarction. J Am Soc Nephrol. 2005 Oct 19

Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, STEHMAN_BREEN C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005 May 19;352(20):2049-60.

Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, STEHMAN-BREEN C, Toto RD, Pfeffer MA. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar;149(3):408-13.

Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, STEHMAN-BREEN C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005 Apr 13;293(14):1737-45.

Sarnak MJ, Katz R, STEHMAN-BREEN CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG; Cardiovascular Health Study. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005 Apr 5;142(7):497-505. Summary for patients in: Ann Intern Med. 2005 Apr 5;142(7):I53.

Colloton M, Shatzen E, Miller G, STEHMAN-BREEN C, Wada M, Lacey D, Martin D. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005 Feb;67(2):467.

Shlipak MG, Katz R, Fried LF, Jenny NS, STEHMAN-BREEN CO, Newman AB, Siscovick D, Psaty BM, Sarnak MJ. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005 Jan 18;45(2):268-71. Erratum in: J Am Coll Cardiol. 2005Mar 1;45(5):811.

Shlipak MG Katz R, Cushman M, Sarnak MJ, STEHMAN-BREEN C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 2005 Dec;118(12):1416.

O'Hare AM, Newman AB, Katz R, Fried LF, STEHMAN-BREEN C, Seliger SL, Siscovick DS, Shlipak MG.  Cystatin C and incident peripheral arterial disease events in the elderly:results from the Cardiovascular Health Study. Arch Intern Med. 2005 Dec 12-26;165(22):2666-70.

Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, STEHMAN-BREEN C, Gillen D, Bleyer AJ, Hirsch C, Siscovick D, Newman AB. Kidney Function as a Predictor of Noncardiovascular Mortality. J Am Soc Nephrol. 2005 Dec;16(12):3728-35.

Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, STEHMAN-BREEN C, Sarnak M, Siscovick D, Harris T, Cauley J, Newman AB, Robbins J. Association of Kidney Function with Incident Hip Fracture in Older Adults. J Am Soc Nephrol. 2006 Dec 13

Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, STEHMAN-BREEN C. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
J Intern Med. 2006 Dec;260(6):577-85.

·Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, STEHMAN-BREEN C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006 Aug 15;145(4):237-46.

Fried LF, Shlipak MG, STEHMAN-BREEN C, Mittalhenkle A, Seliger S, Sarnak M, Robbins J, Siscovick D, Harris TB, Newman AB, Cauley JA. Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci. 2006 Jul;61(7):743-8.

Warady BA, Arar MY, Lerner G, Nakanishi AM, STEHMAN-BREEN C. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.
Pediatr Nephrol. 2006 Aug;21(8):1144-52.

Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, STEHMAN-BREEN C. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.  J Intern Med. 2006 Dec;260(6):577-85

Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, STEHMAN-BREEN C, Sarnak M, Siscovick D, Harris T, Cauley J, Newman AB, Robbins J. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007 Jan;18(1):282-6. Epub 2006 Dec 13.

Kestenbaum B, Rudser KD, Shlipak MG, Fried LF, Newman AB, Katz R, Sarnak MJ, Seliger S, STEHMAN-BREEN C, Prineas R, Siscovick DS. Kidney function, electrocardiographic findings, and cardiovascular events among older adults. Clin J Am Soc Nephrol. 2007 May;2(3):501-8. Epub 2007 Apr 11.

Wattanakit K, Cushman M, STEHMAN-BREEN C, Heckbert SR, Folsom AR. Chronic Kidney Disease Increases Risk for Venous Thromboembolism. J Am Soc Nephrol. 2007 Nov 21

Gillen DL, STEHMAN-BREEN CO, Smith JM, McDonald RA, Warady BA, Brandt JR, Wong CS. Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation.Am J Transplant. 2008 Dec;8(12):2600-6. Epub 2008 Sep 18.

Silver MR, Agarwal A, Krause M, Lei L, STEHMAN-BREEN C. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease. Am J Geriatr Pharmacother. 2008 Jun;6(2):49-60.

Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI; Dialysis Access Consortium Study Group. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008 May 14;299(18):2164-71.

Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, STEHMAN-BREEN C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. Epub 2008 Apr 16.

Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, Palmas W, STEHMAN-BREEN C, Siscovick DS. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med. 2008 Apr 1;148(7):501

Last Reviewed on 12/10/2014

FacBio XML parser code Epi